Regulation of microRNAs by epigenetics and their interplay involved in cancer

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Liu, Xiaolan ^a,b,c   Chen, Xiaoyan ^a,b,c   Yu, Xinfang ^a,b,c   Tao, Yongguang ^a,b,c   Bode, Ann M ^d   Dong, Zigang ^d   Cao, Ya ^a,b,c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c BEIJING HOSPITAL   (China)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cancer; DNA methylation; Epigenetic; Histone modification; microRNA

Indexed keywords

3 DEAZANEPLANOCIN A; 5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DNA; HISTONE; MICRORNA; MICRORNA 1; MICRORNA 124; MICRORNA 125B; MICRORNA 126; MICRORNA 132; MICRORNA 145; MICRORNA 15A; MICRORNA 16; MICRORNA 205; MICRORNA 26A; MICRORNA 29; MICRORNA 31; MICRORNA 9; TRICHOSTATIN A; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; CANCER CELL; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL ADENOMA; CUTANEOUS T CELL LYMPHOMA; DNA METHYLATION; DOWN REGULATION; EPIGENETIC REPRESSION; EPIGENETICS; GENE EXPRESSION; GENE SILENCING; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; MANTLE CELL LYMPHOMA; MELANOMA; MYELODYSPLASTIC SYNDROME; NEOPLASM; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; STOMACH CANCER; T CELL LEUKEMIA;

EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; MICRORNAS; NEOPLASMS;

EID: 84887945648     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-96     Document Type: Review

References (68)

1. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Proc Natl Acad Sci U S A 2004 101 2999 3004 10.1073/pnas.0307323101 14973191 (Pubitemid 38327724)
2. Genome-wide profiling of chromatin signatures reveals epigenetic regulation of microRNA genes in colorectal cancer. Suzuki H, Takatsuka S, Akashi H, Yamamoto E, Nojima M, Maruyama R, Kai M, Yamano H-o, Sasaki Y, Tokino T, Cancer Res 2011 71 5646 5658 10.1158/0008-5472.CAN-11-1076 21734013
3. Interplay between microRNAs and the epigenetic machinery: an intricate network. Iorio MV, Piovan C, Croce CM, Biochim Biophys Acta Gene Regul Mech 2010 1799 694 701 10.1016/j.bbagrm.2010.05.005
4. Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. Lee K-H, Lotterman C, Karikari C, Omura N, Feldmann G, Habbe N, Goggins MG, Mendell JT, Maitra A, Pancreatology 2009 9 293 301 10.1159/000186051 19407485
5. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, Jones PA, Cancer Cell 2006 9 435 443 10.1016/j.ccr.2006.04.020 16766263 (Pubitemid 43832188)
6. Epigenetic regulation of microRNAs in cancer: an integrated review of literature. Kunej T, Godnic I, Ferdin J, Horvat S, Dovc P, Calin GA, Mutat Res 2011 717 77 84 10.1016/j.mrfmmm.2011.03.008 21420983
7. Principles and challenges of genome-wide DNA methylation analysis. Laird PW, Nat Rev Genet 2010 11 191 203 20125086
8. Epigenetic architecture and miRNA: reciprocal regulators. Wiklund ED, Kjems J, Clark SJ, Epigenomics 2010 2 823 840 10.2217/epi.10.51 22122085
9. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C, Proc Natl Acad Sci 2007 104 15805 15810 10.1073/pnas.0707628104 17890317 (Pubitemid 350035380)
10. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-cell lymphomas. Zhang X, Zhao X, Fiskus W, Lin J, Lwin T, Rao R, Zhang Y, Chan JC, Fu K, Marquez VE, Cancer Cell 2012 22 506 523 10.1016/j.ccr.2012.09.003 23079660
11. Polycomb recruitment to DNA in vivo by the YY1 REPO domain. Wilkinson FH, Park K, Atchison ML, Proc Natl Acad Sci 2006 103 19296 19301 10.1073/pnas.0603564103 17158804 (Pubitemid 46026026)
12. YY1 restrained cell senescence through repressing the transcription of p16. Wang X, Feng Y, Xu L, Chen Y, Zhang Y, Su D, Ren G, Lu J, Huang B, Biochim Biophys Acta 1876 2008 1783
13. Recruitment of HDAC4 by transcription factor YY1 represses HOXB13 to affect cell growth in AR-negative prostate cancers. Ren G, Zhang G, Dong Z, Liu Z, Li L, Feng Y, Su D, Zhang Y, Huang B, Lu J, Int J Biochem Cell Biol 2009 41 1094 1101 10.1016/j.biocel.2008.10.015 19013255
14. NF-κB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Wang H, Garzon R, Sun H, Ladner KJ, Singh R, Dahlman J, Cheng A, Hall BM, Qualman SJ, Chandler DS, Cancer Cell 2008 14 369 381 10.1016/j.ccr.2008.10.006 18977326
15. Sp1/NFκB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Liu S, Wu L-C, Pang J, Santhanam R, Schwind S, Wu Y-Z, Hickey CJ, Yu J, Becker H, Maharry K, et al. Cancer Cell 2010 17 333 347 10.1016/j.ccr.2010. 03.008 20385359
16. Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Sampath D, Liu C, Vasan K, Sulda M, Puduvalli VK, Wierda WG, Keating MJ, Blood 2012 119 1162 1172 10.1182/blood-2011-05-351510 22096249
17. RAS is regulated by the let-7 MicroRNA family. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ, Cell 2005 120 635 647 10.1016/j.cell.2005.01.014 15766527 (Pubitemid 40343076)
18. CagA mediates epigenetic regulation to attenuate let-7 expression in Helicobacter pylori-related carcinogenesis. Hayashi Y, Tsujii M, Wang J, Kondo J, Akasaka T, Jin Y, Li W, Nakamura T, Nishida T, Iijima H, Gut 2013 62 1536 1546 10.1136/gutjnl-2011-301625 22936674
19. The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Brueckner B, Stresemann C, Kuner R, Mund C, Musch T, Meister M, Sültmann H, Lyko F, Cancer Res 2007 67 1419 1423 10.1158/0008-5472.CAN-06-4074 17308078 (Pubitemid 46383365)
20. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Proc Natl Acad Sci 2002 99 15524 15529 10.1073/pnas.242606799 12434020 (Pubitemid 35403967)
21. Cocktail of eternity: HDAC meets miR. Wendtner CM, Blood 2012 119 1095 1096 10.1182/blood-2011-12-394494 22308275
22. Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Zhang X, Chen X, Lin J, Lwin T, Wright G, Moscinski LC, Dalton WS, Seto E, Wright K, Sotomayor E, Tao J, Oncogene 2011 31 3002 3008 22002311
23. Pro-tumorigenic effects of miR-31 loss in mesothelioma. Ivanov SV, Goparaju CM, Lopez P, Zavadil J, Toren-Haritan G, Rosenwald S, Hoshen M, Chajut A, Cohen D, Pass HI, J Biol Chem 2010 285 22809 22817 10.1074/jbc.M110.100354 20463022
24. Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Asangani IA, Harms PW, Dodson L, Pandhi M, Kunju LP, Maher CA, Fullen DR, Johnson TM, Giordano TJ, Palanisamy N, Oncotarget 2012 3 1011 1025 22948084
25. miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer. Augoff K, McCue B, Plow EF, Sossey-Alaoui K, Mol Cancer 2012 11 5 10.1186/1476-4598-11-5 22289355
26. Polycomb-mediated loss of miR-31 activates NIK-dependent NF-κB pathway in adult T cell leukemia and other cancers. Yamagishi M, Nakano K, Miyake A, Yamochi T, Kagami Y, Tsutsumi A, Matsuda Y, Sato-Otsubo A, Muto S, Utsunomiya A, Cancer Cell 2012 21 121 10.1016/j.ccr.2011.12.015 22264793
27. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT, Nature 2009 458 762 765 10.1038/nature07823 19219026
28. The NF-κB member p65 controls glutamine metabolism through miR-23a. Rathore MG, Saumet A, Rossi J-F, De Bettignies C, Tempé D, Lecellier C-H, Villalba M, Int J Biochem Cell Biol 2012 44 1448 1456 10.1016/j.biocel. 2012.05.011 22634383
29. HDAC family: what are the cancer relevant targets? Witt O, Deubzer HE, Milde T, Oehme I, Cancer Lett 2009 277 8 21 10.1016/j.canlet.2008.08.016 18824292
30. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. Au SLK, Wong CCL, Lee JMF, Fan DNY, Tsang FH, Ng IOL, Wong CM, Hepatology 2012 56 622 631 10.1002/hep.25679 22370893
31. Histone deacetylases activate hepatocyte growth factor signaling by repressing MicroRNA-449 in hepatocellular carcinoma cells. Buurman R, Gürlevik E, Schäffer V, Eilers M, Sandbothe M, Kreipe H, Wilkens L, Schlegelberger B, Kühnel F, Skawran B, Gastroenterology 2012 143 811 820 e815 10.1053/j.gastro.2012.05.033 22641068
32. Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cao Q, Mani R-S, Ateeq B, Dhanasekaran SM, Asangani IA, Prensner JR, Kim JH, Brenner JC, Jing X, Cao X, Cancer Cell 2011 20 187 199 10.1016/j.ccr.2011. 06.016 21840484
33. Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Bao B, Ali S, Banerjee S, Wang Z, Logna F, Azmi AS, Kong D, Ahmad A, Li Y, Padhye S, Cancer Res 2012 72 335 345 10.1158/0008-5472.CAN-11-2182 22108826
34. Jumonji/ARID1 B (JARID1B) protein promotes breast tumor cell cycle progression through epigenetic repression of microRNA let-7e. Mitra D, Das PM, Huynh FC, Jones FE, J Biol Chem 2011 286 40531 40535 10.1074/jbc.M111.304865 21969366
35. Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. Wang Y, Lee AT, Ma JZ, Wang J, Ren J, Yang Y, Tantoso E, Li K-B, Ooi LLJ, Tan P, J Biol Chem 2008 283 13205 13215 10.1074/jbc.M707629200 18319255
36. MicroRNA-224 is up-regulated in hepatocellular carcinoma through epigenetic mechanisms. Wang Y, Toh HC, Chow P, Chung AY, Meyers DJ, Cole PA, Ooi LL, Lee CG, FASEB J 2012 26 3032 3041 10.1096/fj.11-201855 22459148
37. Discovery pipeline for epigenetically deregulated miRNAs in cancer: integration of primary miRNA transcription. Hulf T, Sibbritt T, Wiklund ED, Bert S, Strbenac D, Statham AL, Robinson MD, Clark SJ, BMC Genomics 2011 12 54 10.1186/1471-2164-12-54 21255435
38. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Greither T, Grochola LF, Udelnow A, Lautenschläger C, Würl P, Taubert H, Int J Cancer 2010 126 73 80 10.1002/ijc.24687 19551852
39. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Jiang S, Zhang H-W, Lu M-H, He X-H, Li Y, Gu H, Liu M-F, Wang E-D, Cancer Res 2010 70 3119 3127 10.1158/0008-5472.CAN- 09-4250 20354188
40. Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. Chang S, Wang R-H, Akagi K, Kim K-A, Martin BK, Cavallone L, Haines DC, Basik M, Mai P, Poggi E, et al. Nat Med 2011 17 1275 1282 10.1038/nm.2459 21946536
41. Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Börno ST, Fischer A, Kerick M, Fälth M, Laible M, Brase JC, Kuner R, Dahl A, Grimm C, Sayanjali B, Cancer Discov 2012 2 1024 1035 10.1158/2159-8290.CD-12-0041 22930729
42. Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis. Balaguer F, Link A, Lozano JJ, Cuatrecasas M, Nagasaka T, Boland CR, Goel A, Cancer Res 2010 70 6609 6618 10.1158/0008-5472.CAN-10-0622 20682795
43. Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Datta J, Kutay H, Nasser MW, Nuovo GJ, Wang B, Majumder S, Liu C-G, Volinia S, Croce CM, Schmittgen TD, Cancer Res 2008 68 5049 5058 10.1158/0008-5472.CAN-07-6655 18593903
44. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CEA, Callegari E, Schwind S, Pang J, Yu J, Muthusamy N, Blood 2009 113 6411 6418 10.1182/blood-2008-07-170589 19211935
45. Aberrant epigenetic grooming of miRNAs in pancreatic cancer: a systems biology perspective. Azmi AS, Beck FW, Bao B, Mohammad RM, Sarkar FH, Epigenomics 2011 3 747 759 10.2217/epi.11.97 22126293
46. Chromatin, cancer and drug therapies. Cortez CC, Jones PA, Mut Res/Fundam Mol Mech Mutagen 2008 647 44 51 10.1016/j.mrfmmm.2008.07.006
47. Epigenetics in cancer: what's the future. Boumber Y, Issa J, Oncology 2011 25 220 226 21548464
48. Cancer epigenetics reaches mainstream oncology. Rodríguez-Paredes M, Esteller M, Nat Med 2011 17 331
49. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Marks PA, Breslow R, Nat Biotechnol 2007 25 84 90 10.1038/nbt1272 17211407 (Pubitemid 46087907)
50. miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. Yang X, Feng M, Jiang X, Wu Z, Li Z, Aau M, Yu Q, Genes Dev 2009 23 2388 2393 10.1101/gad.1819009 19833767
51. Regulation of placenta growth factor by microRNA-125b in hepatocellular cancer. Alpini G, Glaser SS, Zhang JP, Francis H, Han Y, Gong J, Stokes A, Francis T, Hughart N, Hubble L, J Hepatol 2011 55 1339 1345 10.1016/j.jhep.2011. 04.015 21703189
52. Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Saito Y, Friedman JM, Chihara Y, Egger G, Chuang JC, Liang G, Biochem Biophys Res Commun 2009 379 726 731 10.1016/j.bbrc.2008.12.098 19116145
53. Identification of metastamirs as metastasis-associated MicroRNAs in clear cell renal cell carcinomas. Wotschofsky Z, Liep J, Meyer H-A, Jung M, Wagner I, Disch AC, Schaser KD, Melcher I, Kilic E, Busch J, Int J Biol Sci 2012 8 1363 1374 23139634
54. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Körner H, Knyazev P, Diebold J, Hermeking H, Cell Cycle 2008 7 2591 2600 10.4161/cc.7.16.6533 18719384
55. A microRNA DNA methylation signature for human cancer metastasis. Lujambio A, Calin G, Villanueva A, Ropero S, Sánchez-Céspedes M, Blanco D, Montuenga L, Rossi S, Nicoloso M, Faller W, Proc Natl Acad Sci U S A 2008 105 13556 13561 10.1073/pnas.0803055105 18768788
56. miR-370 modulates insulin receptor substrate-1 expression and inhibits the tumor phenotypes of oral carcinoma. Chang K, Chu T, Gong N, Chiang W, Yang C, Liu C, Wu C, Lin S, Oral Dis 2013 19 611 619 10.1111/odi.12046 23231387
57. Methyl-CpG binding protein MBD2 is implicated in methylation-mediated suppression of miR-373 in hilar cholangiocarcinoma. Chen Y, Gao W, Luo J, Tian R, Sun H, Zou S, Oncol Rep 2011 25 443 21165562
58. miR193b is an epigenetically regulated putative tumor suppressor in prostate cancer. Rauhala HE, Jalava SE, Isotalo J, Bracken H, Lehmusvaara S, Tammela TLJ, Oja H, Visakorpi T, Int J Cancer 2010 127 1363 1372 10.1002/ijc.25162 20073067
59. DNA methylation silences miR-132 in prostate cancer. Formosa A, Lena A, Markert E, Cortelli S, Miano R, Mauriello A, Croce N, Vandesompele J, Mestdagh P, Finazzi-Agrò E, Oncogene 2012 32 127 134 22310291
60. The functional significance of microRNA-145 in prostate cancer. Zaman M, Chen Y, Deng G, Shahryari V, Suh S, Saini S, Majid S, Liu J, Khatri G, Tanaka Y, Br J Cancer 2010 103 256 264 10.1038/sj.bjc.6605742 20588276
61. Epigenetic silencing of miR-335 and its host gene MEST in hepatocellular carcinoma. Dohi O, Yasui K, Gen Y, Takada H, Endo M, Tsuji K, Konishi C, Yamada N, Mitsuyoshi H, Yagi N, Int J Oncol 2013 42 411 418 23229728
62. Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Bhatnagar N, Li X, Padi S, Zhang Q, Tang M, Guo B, Cell Death Dis 2010 1 105 10.1038/cddis.2010.85 21368878
63. MicroRNA let-7 suppresses nasopharyngeal carcinoma cells proliferation through downregulating c-Myc expression. Wong T-S, Man O-Y, Tsang C-M, Tsao S-W, Tsang RK-Y, Chan JY-W, Ho W-K, Wei WI, To VS-H, J Cancer Res Clin Oncol 2011 137 415 422 10.1007/s00432-010-0898-4 20440510
64. Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR1792 cluster. Humphreys KJ, Cobiac L, Le Leu RK, Van der Hoek MB, Michael MZ, Mol Carcinog 2013 52 459 474 10.1002/mc.21879 22308110
65. Cancer research: past, present and future. Cao Y, DePinho RA, Ernst M, Vousden K, Nat Rev Cancer 2011 11 749 754 10.1038/nrc3138 21918542
66. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Koh CM, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S, De Marzo AM, Oncotarget 2011 2 669 21941025
67. Widespread microRNA repression by Myc contributes to tumorigenesis. Chang T-C, Yu D, Lee Y-S, Wentzel EA, Arking DE, West KM, Dang CV, Thomas-Tikhonenko A, Mendell JT, Nat Genet 2007 40 43 50 18066065
68. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler HA, Barth TF, Möller P, Stilgenbauer S, Pollack JR, Wirth T, Blood 2008 112 4202 4212 10.1182/blood-2008-03-147645 18713946